力尔凡膀胱灌注预防非肌层浸润性膀胱癌复发的对照研究  

A Control Study of Intravesical Lifein in Preventing Recurrence of Non-muscle Invasive Bladder Cancer

作　　者：孙凯[1] 张奇夫 

机构地区：[1]吉林省肿瘤医院泌尿外科,130012

出　　处：《实用癌症杂志》2014年第5期583-586,共4页The Practical Journal of Cancer

摘　　要：目的评价力尔凡膀胱灌注预防非肌层浸润性膀胱癌的有效性及安全性。方法采用单中心、前瞻性研究方法,将非肌层浸润性膀胱癌132例随机分为2组:对照组(66例)经尿道膀胱肿瘤电切术(TURBt)后24 h内,给予羟基喜树碱或吡柔比星;治疗组(66例)则在对照组基础上灌注力尔凡,随访2年,观察总复发率、平均复发时间等。结果治疗组2年复发率(21.6%vs 33.3%,P<0.011)及G3分级复发的风险(38.4%vs 75.0%,P=0.036)显著低于对照组,并具有统计学差异,但生存曲线分析显示力尔凡可能延长患者的生存时间(χ2=5.655,P=0.017)。不良反应主要为血尿和膀胱炎。结论力尔凡有助于降低非肌层膀胱癌的复发率,延长复发时间及患者生存周期,其机制可能与促进IL-2及IFN-γ表达有关。Objective To evaluate the efficacy and safety of LIFEIN in preventing recurrence of Non-muscle invasive bladder cancer .Methods A single-center randomized ,prospective clinical study was conducted .134 Non-muscle invasive blad-der cancer（NMIBC） patients were included.The control group（N=66） was given Hydroxycamptothecin or pirarubicin by intra-vesical instillation 24 hours after treated by transurethral resection of bladder tumor .The treatment group （ N=66 ） was given Lifein by intravesical instillation on basis of the control group .The patients were followed-up for 2 years to evaluate the total recur-rence rate,mean recurrence time,grading recurrence rate.Results In the treatment group,2-year recurrence rate （21.6%vs 33.3%,P〈0.011）,mean recurrence time（18.65 ＆#177;3.2 vs 15.02 ＆#177;3.24,P=0.00） and recurrence of G3（38.4%vs75.0%,P=0.036）were lower than that of the control group ,the difference was statistically significant .The survival curve showed that Lifein could prolong the survival time （χ2 =5.655,P=0.017）.Hematuresis and urocystitis were the main adverse reactions . Conclusion Lifein can decrease recurrence rate of NMIBC and prolong the recurrence time and survival time of patients ,and the mechanism is probably related with promoting expression of IL-2 and IFN-γ.

关 键 词：非肌层浸润性膀胱癌 力尔凡 复发 

分 类 号：R737.14[医药卫生—肿瘤]